Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
17.53
-0.04 (-0.23%)
At close: Feb 9, 2026, 4:00 PM EST
17.18
-0.35 (-2.00%)
After-hours: Feb 9, 2026, 5:56 PM EST

Keros Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
246.723.550.15-20.1-
Revenue Growth (YoY)
37798.31%2250.99%----
Cost of Revenue
154.96173.63135.2687.2755.1433.86
Gross Profit
91.76-170.08-135.11-87.27-35.04-33.86
Selling, General & Admin
45.2740.7534.8327.5321.3312.8
Operating Expenses
45.2740.7534.8327.5321.3312.8
Operating Income
46.49-210.83-169.94-114.79-56.37-46.66
Interest Expense
----0-0-0.01
Interest & Investment Income
27.3623.514.763.640.03-
Currency Exchange Gain (Loss)
-1.04-0.95-0.21-0.61--
Other Non Operating Income (Expenses)
1.241.242.47.08-0.381.13
Pretax Income
71.15-187.05-152.99-104.68-56.73-45.53
Income Tax Expense
6.70.3--2.01-0.17
Net Income
64.45-187.35-152.99-104.68-58.74-45.36
Net Income to Common
64.45-187.35-152.99-104.68-58.74-45.36
Shares Outstanding (Basic)
413729252316
Shares Outstanding (Diluted)
413729252316
Shares Change (YoY)
17.52%27.13%16.66%8.17%50.48%566.41%
EPS (Basic)
1.59-5.00-5.20-4.15-2.52-2.93
EPS (Diluted)
1.57-5.00-5.20-4.15-2.52-2.93
Free Cash Flow
87.08-162.8-126.97-71.3-63.17-37.19
Free Cash Flow Per Share
2.12-4.35-4.31-2.83-2.71-2.40
Gross Margin
37.19%----174.34%-
Operating Margin
18.84%-5938.96%-112543.71%--280.46%-
Profit Margin
26.12%-5277.55%-101319.21%--292.26%-
Free Cash Flow Margin
35.30%-4585.91%-84087.42%--314.29%-
EBITDA
47.93-209.6-169.13-114.12-56-46.38
EBITDA Margin
19.43%----278.58%-
D&A For EBITDA
1.441.230.820.670.380.28
EBIT
46.49-210.83-169.94-114.79-56.37-46.66
EBIT Margin
18.84%----280.46%-
Revenue as Reported
246.723.550.15-20.1-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q